TRVI - NASDAQ

Trevi Therapeutics, Inc.

TRVI·NASDAQ

$13.45

-3.6%

HealthcareBiotechnology

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.91B

EPS-0.2900

P/E Ratio-46.38

Earnings Date08/06/2026

trvi

Additional Paid-In Capital

Last Annual Value

512.77M

3-Year CAGR

17%

5-Year CAGR

24%

10-Year CAGR

Adjust for Inflation

Trevi Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital

TRVI · NASDAQ

Company	Additional Paid-In Capital	CAGR 3Y	CAGR 5Y	CAGR 10Y
Trevi Therapeutics, Inc. NASDAQ:TRVI	512.77M	16.8%	21.0%	N/A
Ardelyx, Inc. NASDAQ:ARDX	1.11B	3.2%	7.0%	10.6%
Zenas BioPharma, Inc. NASDAQ:ZBIO	1.01B	500.8%	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	1.08B	17.8%	15.7%	N/A
Novavax, Inc. NASDAQ:NVAX	4.54B	2.7%	6.3%	17.1%
Precigen, Inc. NASDAQ:PGEN	0.00	N/A	N/A	N/A
Tourmaline Bio, Inc. NASDAQ:TRML	435.01M	17.7%	5.4%	N/A
Terns Pharmaceuticals, Inc. NASDAQ:TERN	0.00	N/A	N/A	N/A
Upstream Bio, Inc. NASDAQ:UPB	660.60M	415.4%	N/A	N/A

Trevi Therapeutics, Inc. Fair Value Envelope

TRVI · NASDAQ

Our analysis suggests that TRVI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.45, this represents a potential HIDDEN relative to our calculated worth for Trevi Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $13.45

Related Guides

Blog Categories

Continue your TRVI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.